Biotechnology

YIELD10 BIOSCIENCE INC

YIELD10 BIOSCIENCE INC released FY2024 H1 earnings on August 14 (EST), actual revenue 750 K USD, actual EPS -9.8365

Yield10 Bioscience Inc. released FY2023 Q2 earnings on August 14 (EST), with actual revenue of 0 and EPS of -15.4199

Yield10 Bioscience Inc. released FY2023 Q3 earnings on August 14 (EST), with actual revenue of 0 and EPS of -9.9492

YIELD10 BIOSCIENCE INC released FY2024 Q2 earnings on August 14 (EST), actual revenue 450 K USD (forecast 300 K USD), actual EPS -5.0401

YIELD10 BIOSCIENCE INC released FY2023 Cumulative 3Q earnings on August 14, 2024 (EST), with actual revenue of 60 K USD and EPS of -43.5292

Yield10 Bioscience Inc. released FY2023 H1 earnings on August 14 (EST), with actual revenue of 60K USD and EPS of -33.3761

Yield10 Bioscience Inc. released FY2023 Q1 earnings on May 15, 2024 (EST), with actual revenue of 60K USD and EPS of -18.16

YIELD10 BIOSCIENCE INC released FY2024 Q1 earnings on May 15 (EST), actual revenue 300K USD, actual EPS -4.7699

Yield10 Bioscience Inc. released FY2022 annual earnings on April 1, 2024 (EST), with actual revenue of $450,000 (forecasted $488,000) and EPS of -66.2486

YIELD10 BIOSCIENCE INC released FY2022 Q4 earnings on April 1, 2024 (EST), with actual revenue of 87K USD and EPS of -16.0348

Yield10 Bioscience Inc. released FY2023 Q4 earnings on April 1, 2024 (EST), with actual revenue of 0 and EPS of -6.5426

YIELD10 BIOSCIENCE INC released FY2023 Annual Earnings on April 1, 2024 (EST), Revenue: 60K USD, EPS: -43.6581

Yield10 Bioscience Inc. released FY2022 Q3 earnings on November 14 (EST), actual revenue 111K USD (forecast 133K USD), actual EPS -17.0035

< 1B

1B - 5B

5B - 10B

10B - 50B

50B - 100B

100B - 500B

500B - 1T

≥ 1T

Market Value

Total Assets

< 100M

100M - 500M

500M - 1B

≥ 100B

Revenue

0 - 50M

50M - 100M

≥ 10B

Profits

< 0%

0% - 5%

5% - 10%

10 - 15%

15% - 20%

20 - 25%

25% - 30%

>= 30%

ROE(TTM)

= 0%

0% - 1%

1% - 3%

3% - 5%

5% - 8%

8% - 10%

>= 10%

Dividend Yield

0% - 10%

10% - 15%

20% - 30%

30% - 40%

40% - 50%

>= 50%

Net Profit Margin

0 - 0.05

0.05 - 0.1

0.1 - 0.2

0.2 - 0.4

0.4 - 0.6

0.6 - 0.8

0.8 - 1

>= 1

Asset Turnover

< 1.5

1.5 - 2

2 - 3

3 - 5

5 - 10

10 - 15

15 - 20

>= 20

Equity Multiplier

< 10%

10% - 30%

30% - 50%

50% - 70%

70 - 80%

80% - 90%

90% - 95%

>= 95%

Debt Ratio

Movano

Direct Digital

Brand Engagement Network

Tryhard

UY SCUTI ACQUISITION CORP COM USD0.0001(S/R) 03/03/2030

BlackRock Corporate High Yield Fund, Inc.

Austin Gold

Kustom ENT

Q/C Tech

GIBO

Adma Biologics

Kiniksa Pharmaceuticals

Stoke Therapeutics

Rigel Pharma

OpGen

Vertex Pharma

Regeneron Pharma

Argenx

Alnylam Pharma

Beigene

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap

Ownership	%Owned	Share Chg	Report Date
Jack W. Schuler	8.88%	No Change	11/10/2024
Oliver P. Peoples	2.85%	No Change	11/10/2024
Kristi D. Snell	1.87%	No Change	11/10/2024
Lynne H. Brum	1.71%	No Change	11/10/2024
Charles B. Haaser	0.82%	No Change	15/08/2024
Richard William Hamilton	0.41%	No Change	11/10/2024
Robert L. Van Nostrand	0.28%	No Change	11/10/2024
Schuler Family Foundation	0.19%	No Change	24/04/2024
Renate R. Schuler	0%	No Change	24/04/2024

YIELD10 BIOSCIENCE INC(YTENQ.US)

Financial Score

Valuation analysis

Institutional View & Shareholder

Analyst Ratings